PURPOSE: Excessive orbital fibroblast proliferation and hyaluronan production are characteristic of Graves' ophthalmopathy (GO) and are driven by local mediators. Imatinib mesylate and AMN107 are tyrosine kinase inhibitors that inhibit fibroblast proliferation and collagen production in lungs and skin. This study was conducted to determine whether imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB and TGF-beta(1) and whether expression of the genes PDGF-B and TGF-B(1) (growth factors suggested to play a role in GO) are increased in GO orbital tissues. METHODS: PDGF-B and TGF-B(1) mRNA levels were determined in orbital tissues of 13 patients with GO and 5 control patients. Orbital fibroblasts were cultured from eight patients with GO and three control patients and the effect of imatinib mesylate and AMN107 on PDGF-BB and TGF-beta(1)-induced orbital fibroblast proliferation, signaling cascades, hyaluronan synthase (HAS) gene expression and hyaluronan production were determined. RESULTS: PDGF-B and TGF-B(1) mRNA levels were significantly increased in GO orbital tissues. Imatinib mesylate and AMN107 inhibited PDGF-BB-induced orbital fibroblast proliferation, HAS induction and hyaluronan production by blocking PDGF-receptor phosphorylation. TGF-beta(1) induced HAS expression and hyaluronan production. This induction was not inhibited by imatinib mesylate or AMN107, due to the inability of TGF-beta(1) to activate c-Abl kinase activity in orbital fibroblasts. CONCLUSIONS: Imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB; a factor highly expressed in orbital tissue from patients with GO. The drugs, however, had no effect on TGF-beta(1)-induced HAS expression and hyaluronan production. Nevertheless, imatinib mesylate and AMN107 should be considered as treatment candidates for GO.
PURPOSE: Excessive orbital fibroblast proliferation and hyaluronan production are characteristic of Graves' ophthalmopathy (GO) and are driven by local mediators. Imatinib mesylate and AMN107 are tyrosine kinase inhibitors that inhibit fibroblast proliferation and collagen production in lungs and skin. This study was conducted to determine whether imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB and TGF-beta(1) and whether expression of the genes PDGF-B and TGF-B(1) (growth factors suggested to play a role in GO) are increased in GO orbital tissues. METHODS: PDGF-B and TGF-B(1) mRNA levels were determined in orbital tissues of 13 patients with GO and 5 control patients. Orbital fibroblasts were cultured from eight patients with GO and three control patients and the effect of imatinib mesylate and AMN107 on PDGF-BB and TGF-beta(1)-induced orbital fibroblast proliferation, signaling cascades, hyaluronan synthase (HAS) gene expression and hyaluronan production were determined. RESULTS: PDGF-B and TGF-B(1) mRNA levels were significantly increased in GO orbital tissues. Imatinib mesylate and AMN107 inhibited PDGF-BB-induced orbital fibroblast proliferation, HAS induction and hyaluronan production by blocking PDGF-receptor phosphorylation. TGF-beta(1) induced HAS expression and hyaluronan production. This induction was not inhibited by imatinib mesylate or AMN107, due to the inability of TGF-beta(1) to activate c-Abl kinase activity in orbital fibroblasts. CONCLUSIONS: Imatinib mesylate and AMN107 inhibit orbital fibroblast proliferation and hyaluronan production induced by PDGF-BB; a factor highly expressed in orbital tissue from patients with GO. The drugs, however, had no effect on TGF-beta(1)-induced HAS expression and hyaluronan production. Nevertheless, imatinib mesylate and AMN107 should be considered as treatment candidates for GO.
Authors: Tatiana V Beketova; Mikhail Y Volkov; Evgeniy A Naryshkin; Tatiana M Novoselova; Evgeniy L Nasonov Journal: Clin Rheumatol Date: 2018-03-21 Impact factor: 2.980
Authors: Naxin Guo; Carolyn J Baglole; Charles W O'Loughlin; Steven E Feldon; Richard P Phipps Journal: J Biol Chem Date: 2010-03-22 Impact factor: 5.157
Authors: Sita Virakul; Leendert van Steensel; Virgil A S H Dalm; Dion Paridaens; P Martin van Hagen; Willem A Dik Journal: Eur Thyroid J Date: 2014-12-06
Authors: Clément M L Werner; Stefan M Zimmermann; Carola C Würgler-Hauri; Joseph M Lane; Guido A Wanner; Hans-Peter Simmen Journal: HSS J Date: 2013-06-21
Authors: Jeroen Bastiaans; Jan C van Meurs; Conny van Holten-Neelen; Marja Smits-Te Nijenhuis; Marion J Kolijn-Couwenberg; P Martin van Hagen; Robert W A M Kuijpers; Herbert Hooijkaas; Willem A Dik Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-04-20 Impact factor: 3.117
Authors: Sita Virakul; Virgil A S H Dalm; Dion Paridaens; Willem A van den Bosch; Nattiya Hirankarn; P Martin van Hagen; Willem A Dik Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-05-30 Impact factor: 3.117
Authors: Ajay E Kuriyan; Collynn F Woeller; Charles W O'Loughlin; Richard P Phipps; Steven E Feldon Journal: Invest Ophthalmol Vis Sci Date: 2013-11-08 Impact factor: 4.799